Associations - CHEK2 (Checkpoint kinase 2)

CHEK2 mutation	Prostate Cancer	CHEK2 mutation	Prostate Cancer	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2
CHEK2 mutation	Ovarian Cancer	CHEK2 mutation	Ovarian Cancer	olaparib Sensitive: B - Late Trials olaparib Sensitive : B	olaparib Sensitive: B - Late Trials olaparib Sensitive : B
CHEK2 mutation	HER2 Negative Breast Cancer	CHEK2 mutation	HER2 Negative Breast Cancer	durvalumab Sensitive: C2 – Inclusion Criteria durvalumab Sensitive : C2	durvalumab Sensitive: C2 – Inclusion Criteria durvalumab Sensitive : C2
CHEK2 mutation	Prostate Cancer	CHEK2 mutation	Prostate Cancer	rucaparib Sensitive: C2 – Inclusion Criteria rucaparib Sensitive : C2	rucaparib Sensitive: C2 – Inclusion Criteria rucaparib Sensitive : C2
CHEK2 mutation + ATM mutation + BRCA2 mutation	Non Small Cell Lung Cancer	CHEK2 mutation + ATM mutation + BRCA2 mutation	Non Small Cell Lung Cancer	cetuximab + avelumab Sensitive: C3 – Early Trials cetuximab + avelumab Sensitive : C3	cetuximab + avelumab Sensitive: C3 – Early Trials cetuximab + avelumab Sensitive : C3
CHEK2 mutation	HER2 Negative Breast Cancer	CHEK2 mutation	HER2 Negative Breast Cancer	talazoparib Sensitive: C3 – Early Trials talazoparib Sensitive : C3	talazoparib Sensitive: C3 – Early Trials talazoparib Sensitive : C3
BRCA2 mutation + CHEK2 mutation	Prostate Cancer	BRCA2 mutation + CHEK2 mutation	Prostate Cancer	GnRH stimulant Resistant: C3 – Early Trials GnRH stimulant Resistant : C3	GnRH stimulant Resistant: C3 – Early Trials GnRH stimulant Resistant : C3
CHEK2 mutation	Breast Cancer	CHEK2 mutation	Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3
CHEK2 mutation	Pancreatic Ductal Adenocarcinoma	CHEK2 mutation	Pancreatic Ductal Adenocarcinoma	irinotecan Sensitive: C3 – Early Trials irinotecan Sensitive : C3	irinotecan Sensitive: C3 – Early Trials irinotecan Sensitive : C3
CHEK2 mutation	Tongue Carcinoma	CHEK2 mutation	Tongue Carcinoma	ABT-888 + M6620 Sensitive: C4 – Case Studies ABT-888 + M6620 Sensitive : C4	ABT-888 + M6620 Sensitive: C4 – Case Studies ABT-888 + M6620 Sensitive : C4
BRCA2 mutation + CHEK2 mutation	Pancreatic Adenocarcinoma	BRCA2 mutation + CHEK2 mutation	Pancreatic Adenocarcinoma	FOLFIRINOX Sensitive: C4 – Case Studies FOLFIRINOX Sensitive : C4	FOLFIRINOX Sensitive: C4 – Case Studies FOLFIRINOX Sensitive : C4
CHEK2 mutation	Testicular Cancer	CHEK2 mutation	Testicular Cancer	talazoparib Sensitive: C4 – Case Studies talazoparib Sensitive : C4	talazoparib Sensitive: C4 – Case Studies talazoparib Sensitive : C4
CHEK2 mutation	Prostate Cancer	CHEK2 mutation	Prostate Cancer	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4

CHEK2 (Checkpoint kinase 2)

Associations(13)

Associations
(13)